Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Gilead ( GILD) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.1%. By the end of trading, Gilead fell $0.76 (-1.3%) to $58.17 on light volume. Throughout the day, 4,974,143 shares of Gilead exchanged hands as compared to its average daily volume of 9,920,100 shares. The stock ranged in price between $58.14-$59.56 after having opened the day at $59.11 as compared to the previous trading day's close of $58.93. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 42.2%, Osiris Therapeutics ( OSIR), down 11.8%, China Pharma ( CPHI), down 11.6% and Cardium Therapeutics ( CXM), down 11.1%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $90.2 billion and is part of the health care sector. Shares are up 60.5% year to date as of the close of trading on Tuesday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, Skystar Bio-Pharmaceutical Company ( SKBI), up 82.5%, Columbia Laboratories ( CBRX), up 17.1%, GW Pharmaceuticals PLC ADR ( GWPH), up 16.9% and Anacor Pharmaceuticals ( ANAC), up 15.9% , were all gainers within the drugs industry with Actavis ( ACT) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

U.S. Earnings On Pace for Best Season in Two Decades but Tech Giants Await

U.S. Earnings On Pace for Best Season in Two Decades but Tech Giants Await

Alphabet Earnings and 4 Other Business Stories You Must Know Monday Morning

Alphabet Earnings and 4 Other Business Stories You Must Know Monday Morning

Alphabet Earnings, Bond Yields Rise, Akorn Plunges - 5 Things You Must Know

Alphabet Earnings, Bond Yields Rise, Akorn Plunges - 5 Things You Must Know

Global Stocks Slip as 3% 10-Year Yields, Bad Tech News Unsettle Markets

Global Stocks Slip as 3% 10-Year Yields, Bad Tech News Unsettle Markets